We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Innovative Face Mask Inactivates Flu Viruses

By HospiMedica International staff writers
Posted on 03 Apr 2012
An antiviral medical facemask inactivates 99.99% of laboratory tested influenza viruses, including both pandemic and seasonal strains of the flu. More...


The Biofriend BioMask works by using a combination of citric acid, zinc, and copper in different layers of the mask. A hydrophilic coating on the outside quickly wicks droplets into and away from the outer surface. Viruses are inactivated on this outer layer by exposure to citric acid, which creates a low pH environment. The droplet then lands on the mask's inner (blue) layer, where influenza viruses are inactivated by copper and zinc, which are toxic to the pathogens.

Another benefit of the mask is that it can minimize cross contamination. Commonly, the outer facing of the mask is frequently touched by the user, who then touches other things or people; but since the BioMask absorbs infectious droplets and inactivates the viruses, the risk of spreading the virus is greatly reduced. The Biofriend BioMask is a product of Filligent (Hong Kong SAR, China), and has been approved by the US Food and Drug Administration (FDA). It is distributed as the Curad BioMask in the United States, Canada, and Europe by Medline (Mundelein, IL, USA).

“The key difference with the Curad BioMask is that the BioMask inactivates several common strains of viruses when they come in contact with the mask, while viruses that come in contact with standard masks are just filtered, which means they are still active and potentially infectious to the wearer and others,” said Frank Czajka, president of the Proxima Division at Medline. “Whether you are trying to stop from getting the flu or from sharing it with loved ones, you can feel confident of being protected with Medline's Curad BioMask because it is the only mask available today that actively breaks down viruses.”

In independent laboratory tests, the BioMask inactivated 99.99% of tested influenza viruses upon five minutes contact with the surface of the facemask, including influenza A subtypes and strains, H1N1, H3N2, H2N2; avian flu subtypes H5N1, H9N2, H5N2; swine flu subtype H1N1; equine flu subtype H3N8; and Influenza B strains. It is also effective against tuberculosis (TB), rhinovirus, methicillin-resistant Staphylococcus aureus (MRSA), and measles.

Related Links:
Filligent
Medline


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.